Affimed N.V. (AFMD) Bundle
An Overview of Affimed N.V. (AFMD)
General Summary of Affimed N.V. (AFMD)
Affimed N.V. is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany. The company focuses on developing innovative targeted immunotherapies for cancer treatment.
Key Products and Pipeline:
- AFM13 (NK cell-engaging therapy for CD30-positive lymphomas)
- AFM24 (NKG2D-based bispecific antibody)
- AFM28 (NKG2D-based bispecific antibody)
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $41.7 million |
| Net Loss | $74.3 million |
| Cash and Cash Equivalents | $136.4 million |
Industry Leadership
Affimed N.V. is recognized for its innovative NK cell-engaging immunotherapy platform. The company has strategic collaborations with major pharmaceutical companies including Genentech and Merck.
Key Collaboration Highlights:
- Genentech collaboration for AFM13
- Ongoing clinical trials in multiple cancer indications
- Proprietary TetraNKTM platform technology
Mission Statement of Affimed N.V. (AFMD)
Mission Statement Overview of Affimed N.V. (AFMD)
Affimed N.V. (AFMD) mission statement focuses on advancing targeted cancer immunotherapies through innovative NK cell engager technologies.
Core Mission Components
| Component | Specific Details | 2024 Metrics |
|---|---|---|
| Research Focus | NK cell engager platform | 3 clinical-stage programs |
| Clinical Development | Precision oncology therapeutics | AFM13 and AFM24 in clinical trials |
| Therapeutic Approach | Targeted immunotherapy | $98.4 million cash reserves (Q4 2023) |
Key Strategic Objectives
- Develop novel NK cell engager therapies
- Advance clinical pipeline in oncology
- Leverage proprietary ROCK platform
Scientific Innovation Metrics
Affimed's mission is supported by:
- 8 ongoing clinical trials
- 4 therapeutic candidates in development
- 2 lead programs in solid tumors and hematological malignancies
Therapeutic Technology Platform
| Technology | Capabilities | Current Status |
|---|---|---|
| ROCK Platform | NK cell engagement | Validated in multiple cancer indications |
| NK Cell Engagers | Precision targeting | 3 clinical-stage programs |
Financial Commitment
R&D investment: $52.6 million in 2023
Clinical Development Pipeline
- AFM13: CD30-positive lymphoma
- AFM24: Non-small cell lung cancer
- AFM28: Solid tumor trials
Vision Statement of Affimed N.V. (AFMD)
Vision Statement of Affimed N.V. (AFMD) in 2024
Strategic Focus on Innovative Cancer ImmunotherapiesAffimed N.V. maintains a focused vision centered on developing targeted immunotherapies for cancer treatment. As of Q1 2024, the company's vision encompasses advancing novel NK cell-based and T cell-engaging therapies.
Key Vision Components
Therapeutic Pipeline Objectives| Program | Current Stage | Target Indication |
|---|---|---|
| AFM24 | Phase 1/2 Clinical Trial | Non-Small Cell Lung Cancer |
| AFM13 | Phase 2 Clinical Trial | Hodgkin Lymphoma |
| AFM28 | Preclinical Development | Solid Tumors |
In 2024, Affimed allocated $45.2 million towards research and development expenditures, representing 68% of total operational expenses.
Technological Innovation Priorities
- Advanced NK cell-engaging therapeutics
- Precision T cell redirection technologies
- Multi-specific antibody platforms
Affimed's vision prioritizes clinical advancement across multiple oncology programs, with current focus on:
- Expanding AFM24 clinical trials
- Progressing AFM13 toward potential commercialization
- Accelerating preclinical programs into clinical stages
Financial Performance Alignment
As of December 31, 2023, Affimed reported:
| Financial Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $132.6 million |
| Research and Development Expenses | $45.2 million |
| Net Loss | $63.4 million |
Core Values of Affimed N.V. (AFMD)
Core Values of Affimed N.V. (AFMD) in 2024
Innovation and Scientific ExcellenceAffimed N.V. demonstrates commitment to innovation through its robust research and development pipeline focused on innate cell engagers and NK cell-based therapies.
| R&D Investment | 2024 Amount |
|---|---|
| Total R&D Expenses | $73.4 million |
| Clinical Pipeline Programs | 6 active programs |
Affimed prioritizes patient outcomes through targeted therapeutic development strategies.
- Focus on oncology and immunotherapy treatments
- Clinical trials targeting specific cancer indications
- Precision medicine approach
Strategic partnerships drive scientific advancement and therapeutic innovation.
| Collaborative Partner | Research Focus |
|---|---|
| Genentech | NK cell engager development |
| Roivant Sciences | Immunotherapy research |
Financial and research transparency maintained through comprehensive reporting.
| Financial Metric | 2024 Value |
|---|---|
| Cash and Cash Equivalents | $124.6 million |
| Net Loss | $58.2 million |
Commitment to rigorous scientific standards and ethical research protocols.
- Adherence to FDA and EMA regulatory guidelines
- Comprehensive clinical trial monitoring
- Transparent data reporting
Affimed N.V. (AFMD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.